ORIGINAL ARTICLE   

Italian Journal of Dermatology and Venereology 2022 June;157(3):240-6

DOI: 10.23736/S2784-8671.21.07049-3

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Flares as dynamic predictive factor of response to adalimumab in hidradenitis suppurativa: real-life data

Raffaele D. CAPOSIENA CARO ¹ ✉, Andrea CHIRICOZZI ², Andrea SECHI ³, Elisa MOLINELLI ⁴, Marina VENTURINI ⁵, Eleonora CANDI ⁶, Dalma MALVASO ², Ketty PERIS ², Annalisa PATRIZI ³, Annamaria OFFIDANI ⁴, Piergiacomo CALZAVARA-PINTON ⁵, Luca BIANCHI ¹

¹ Unit of Dermatology, Department of Systems Medicine, Tor Vergata University, Rome, Italy; ² Institute of Dermatology, IRCCS A. Gemelli University Polyclinic Foundation, Sacred Heart Catholic University, Rome, Italy; ³ Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; ⁴ Unit of Dermatology, Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy; ⁵ Department of Dermatology, University of Brescia, ASST Spedali Civili, Brescia, Italy; ⁶ Department of Experimental Medicine, Tor Vergata University, Rome, Italy

BACKGROUND: Hidradenitis suppurativa (HS) is characterized by periodic worsening of both clinical manifestations and symptoms. The aim of this study was to investigate the role of flare outbreak as a possible predictive factor of response to adalimumab.
METHODS: One hundred fifteen HS patients in treatment with adalimumab, with moderate-severe HS, ≥3 abscesses and inflammatory-nodules (ANs) from 5 Italian centers were included in this retrospective analysis. The information about gender, ages at onset/baseline, therapeutic delay, family history, body mass index, smoking, comorbidities, phenotypes, body areas, severity indexes at baseline was collected. Baseline characteristics, total number and timeline of flares were analyzed by regression and survival analysis with Hidradenitis Suppurativa Clinical Response (HiSCR).
RESULTS: During the observational period, 80.9% of patients developed flares, detecting 252 flares. Univariate model identified five factors associated with the absence of response: age (P=0.020), comorbidities (P=0.030), genital-perineal involvement (P=0.004), no response at week 12 (P=0.027), and flares outbreak (P=0.010). Joint analysis of recurrent and terminal events showed a positive correlation between flare recurrence and no response (P<0.001). Among the identified variables associated with poor response to the therapy: occurrence of a flare before week 12 was the one with the highest risk of no response (P<0.001).
CONCLUSIONS: The analysis of a “dynamic” variable, as flares evaluation together with an appropriate clinical baseline assessment can be a useful approach to predict the middle-long-term response to adalimumab.

KEY WORDS: Hidradenitis suppurativa; Adalimumab; Guidelines as topic